Toronto Star offers Predictmedix AI first appearance on the national stage in interview
“What can your AI do that a well-trained doctor or nurse can’t?” Dr Rahul Kushwah, COO of Predictmedix AI Inc (CSE: PMED; OTCQB: PMEDF; FRA:3QP), recently answered these and a number of other good questions in his first interview with a reporter from Canada’s prestigious Toronto Star newspaper. It is the first time Predictmedix’s AI-based diagnostics have been the subject of a national media outlet: https://www.thestar.com/business/this-ai-scanner-promises-to-speed-up-assessment-times-in-hospitals-and-keep-cannabis-off/article_fe3545f4-1c00-508a-8658-c120720d237a.html
Predictmedix is focusing on the large, emerging markets in India and Indonesia. The data gathered there in 200,000 scans so far is continually refining and improving the AI. If the company were to scan 200,000 people in North America as part of a clinical trial, the costs would be in the tens of millions, Kushwah estimates. Thanks to its cooperation with respected medical institutions in India and Indonesia, Predictmedix receives the data at virtually zero cost. According to the company, the accuracy of the diagnosis is already more than 90 per cent.
Incidentally, Kushwah’s answer to the opening question quoted above was: “If you go to a Canadian hospital, the entire triage process takes between 45 minutes and an hour. We are able to reduce that time to less than 20 seconds with our technology because we can capture all the vital signs in a completely non-invasive and non-contact way. The results can be seamlessly integrated into the hospital’s medical system.
Disclaimer: GOLDINVEST Consulting GmbH publishes comments, analyses and news on https://goldinvest.de. These contents serve exclusively the information of the readers and do not represent a call to action, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. Furthermore, they are in no way a substitute for individual expert investment advice and do not constitute an offer to sell the discussed stock(s) or a solicitation to buy or sell securities. It is expressly not a financial analysis, but a promotional/journalistic text. Readers who make investment decisions or execute transactions on the basis of the information provided here do so exclusively at their own risk. There is no contractual relationship between GOLDINVEST Consulting GmbH and its readers or the users of its offers, because our information refers only to the company, but not to the investment decision of the reader.
The acquisition of securities is associated with high risks, which can lead to a total loss of the invested capital. The information published by GOLDINVEST Consulting GmbH and its authors is based on careful research. Nevertheless, any liability for financial losses or the content guarantee for timeliness, accuracy, adequacy and completeness of the articles offered here is expressly excluded. Please also note our terms of use.
Pursuant to §34b WpHG and §48f Abs. 5 BörseG (Austria) we point out that GOLDINVEST Consulting GmbH and/or partners, principals or employees of GOLDINVEST Consulting GmbH hold shares in Predictmedix and therefore a conflict of interest exists. GOLDINVEST Consulting GmbH also reserves the right to buy or sell shares of the company at any time. Furthermore, GOLDINVEST Consulting GmbH is remunerated by Predictmedix for reporting on the company. This is another clear conflict of interest.
